Menu Search
Equities

Nanologica AB (publ)

4YD:FRA

Nanologica AB (publ)

Actions
  • Price (EUR)0.444
  • Today's Change0.033 / 8.03%
  • Shares traded90.00
  • 1 Year change-35.72%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024 08:15 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nanologica AB (publ) is a Sweden-based materials development company. The Company specializes in developing nanoporous materials from nanoporous silica (silicon dioxide) for a variety of applications, ranging from purification to pharmaceutical excipients. The Company's core competency has been developed and expanded in two areas of application, in particular: Drug Delivery and Chromatography, a technology used for the separation and purification of products on the market and in development. The Company's Drug Delivery sector operates within a niche domain of nanocarriers. Nanologica AB (publ)’s drug delivery technology is aimed on absorption of the medicine by the body for drugs that are poorly soluble in water.

  • Revenue in SEK (TTM)6.13m
  • Net income in SEK-79.83m
  • Incorporated2004
  • Employees16.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.